All In Biotech

Drug Trial Radar · NCT04468659

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,400

Planned (sponsor's estimate)

Start

Jul 14, 2020

Primary completion

Dec 21, 2028

Study completion Jan 16, 2031

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Alzheimer's Clinical Trials Consortium; Biogen; National Institute on Aging (NIA)
First posted
Jul 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerability of lecanemab in participants enrolled in the Extension Phase.

Conditions

  • Preclinical Alzheimer's Disease
  • Early Preclinical Alzheimer's Disease

Interventions

  • LecanemabDrug

    IV infusion.

  • PlaceboDrug

    IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A45 Trial: Change From Baseline in Preclinical Alzheimer Cognitive Composite 5 (PACC5) Score at Week 216Time frame: Baseline, Week 216
  2. A3 Trial: Change From Baseline in Amyloid Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) at Week 216Time frame: Baseline, Week 216

Locations

107 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama, Birmingham

    Birmingham, Alabama

  • Banner Alzheimer's Institute

    Phoenix, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • UCI MIND

    Irvine, California

  • University of Southern California

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Stanford University

    Palo Alto, California

  • Sharp Mesa Vista Hospital

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • University of California, Davis

    Walnut Creek, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • Howard University

    Washington D.C., District of Columbia

  • Advanced Clinical Research Network, Corp

    Coral Gables, Florida

  • Brain Matters Research

    Delray Beach, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • K2 Medical Research - The Villages

    Lady Lake, Florida

  • K2 Medical Research, Llc

    Maitland, Florida

  • Gonzalez MD & Aswad MD Health Sciences

    Miami, Florida

  • Wien Center for Clinical Research

    Miami Beach, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Synexus Clinical Research - Orlando

    Orlando, Florida

  • University of South Florida - Health Byrd Alzheimer Institute

    Tampa, Florida

  • Synexus Clinical Research - The Villages

    The Villages, Florida

  • Alzheimer's Research and Treatment Center

    Wellington, Florida

  • Charter Research

    Winter Park, Florida

  • Emory University

    Atlanta, Georgia

  • Columbus Memory Center

    Columbus, Georgia

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Kansas

    Fairway, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Johns Hopkins University

    Baltimore, Maryland

  • Boston University

    Boston, Massachusetts

  • Brigham and Woman's Hospital Center for Alzheimer Research and Treatment

    Boston, Massachusetts

  • Donald S.Marks, M.D.,P.C.

    Plymouth, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • Washington University, St. Louis

    St Louis, Missouri

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.